Hasan C. Lenk
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Genetic overlap between treatment-resistant schizophrenia and smoking initiation.
Journal: The international journal of neuropsychopharmacology
Published: December 17, 2025
CYP2D6 Genotypes Do Not Affect Clozapine Levels in a Large, Multicenter Cohort: Time Has Come to Revise Food and Drug Administration's Clozapine Packet Insert.
Journal: Schizophrenia bulletin
Published: July 06, 2025
Impact of CYP1A, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and NFIB genotypes on clozapine serum concentration in smokers and nonsmokers.
Journal: Therapeutic advances in psychopharmacology
Published: April 22, 2025
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data.
Journal: CNS drugs
Published: February 29, 2024
Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6-catalyzed metabolism of solanidine.
Journal: Clinical and translational science
Published: October 27, 2023
Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
Journal: Psychiatry research
Published: January 23, 2023
Impact of NFIB and CYP1A variants on clozapine serum concentration-A retrospective naturalistic cohort study on 526 patients with known smoking habits.
Journal: Clinical and translational science
Published: May 25, 2022
The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients.
Journal: Clinical pharmacology and therapeutics
Published: December 16, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026